Report Id: SNS/HC/2655 | July 2022 | Region: Global | 125 Pages
Report Scope & Overview:
The Epilepsy Device Market Size was valued at USD 17.16 billion in 2021 and is expected to reach USD 31.47 billion by 2028, and grow at a CAGR of 9.05% over the forecast period 2022-2028.
Epilepsy is characterised by a sudden and uncontrollable electrical disruption in the brain. It alters the level of feelings, consciousness, movement, and behaviour. Many different forms of epilepsy exist around the world, with varied degrees of severity. Epilepsy types are determined by where and how they begin in the brain. Almost all epilepsy lasts between 30 seconds and 2 minutes.
When epilepsy lasts more than five minutes, medical assistance must be summoned. Epilepsy can develop after a closed head injury, meningitis, or a stroke.
The primary aetiology of epilepsy is unknown. Computed tomography devices, implanted advisory system devices, electromyography machines, magnetic resonance imaging (MRI) devices, and EEG machines are among the most commonly utilised epilepsy detection equipment. If epilepsy is not treated, it frequently results in loss of coordination, vomiting, and nausea.
Epilepsy is becoming more common in the elderly population.
Increased occurrences of brain damage as a result of car accidents
In developing countries, there is a lack of public awareness and availability of epilepsy equipment.
Epilepsy is a chronic neurological illness that can affect persons of any age.
In the future, emerging markets such as Asia-Pacific are likely to boost the industry.
Increased R&D activities related to the use of wearable epilepsy monitoring devices are expected to drive market expansion in the predicted years.
The lack of information for safe device handling, as well as the adverse effects and problems related with this technology, impede market expansion.
The expansion of the epilepsy devices industry is further aided by tissue damage caused by surgery and brain tumours.
IMPACT OF COVID-19:
The demand for medical supplies to care for the afflicted population has increased. Respiratory support devices, such as atomizers, life support machines, oxygen generators, and monitors, are widely utilised in primary clinical care. Furthermore, COVID-19 has resulted in a significant increase in demand for medical goods such as personal protective equipment such as masks, gloves, and protective eyeglasses. Increased demand for medical supplies, both from healthcare professionals and the general public, has significantly contributed to market growth, leading to an increase in the number of COVID-19 cases worldwide.
Manufacturers of these items have the chance to capitalise on increased demand for medical supplies in order to provide a sufficient and constant supply of personal protective equipment in the market. As a result, COVID 19 is projected to have a substantial impact on the market for epilepsy products.
Conventional devices are electroencephalogram (EEG) devices used for continuous patient monitoring. According to WHO, the most accurate predictors of seizure recurrence are good aetiology documentation and an abnormal EEG pattern. As a result, there is a high need for EEG devices used to monitor epileptic patients.
Watches, wristbands, camera devices, mattress gadgets, anti-suffocation pillows, and other wearable devices have been subdivided into the wearable devices section. Seizures can cause symptoms that range from person to person. Despite the fact that there is no quick means to stop a seizure, rapid advances in wearable epileptic device technology have garnered significant popularity in recent years. The vast majority of patients are currently being treated using implanted devices. The FDA has approved three forms of neuromodulation therapy that are achieved through the use of implantable epilepsy devices: vagus nerve stimulation (VNS), deep brain stimulation (DBS), and responsive neurostimulation (RNS).
Vagus Nerve Stimulation (VNS) is an FDA-approved treatment for adults and children who have refractory or medication-resistant epilepsy. It is a neuromodulation technique that uses moderate electrical pulses to send to the brain via the vagus nerve.
Deep Brain Stimulation (DBS) is used when medications no longer work for the patient and is intended to alter how the brain works by sending electrical stimulations to the brain areas implicated in epilepsy.
Accelerometry is a technology that aids in the detection of seizures caused by irregular movements and motor phenomena. Accelerometers are widely employed in wearable epilepsy devices to aid in the identification of seizures.
There are also wireless accelerometry solutions that can be used as an alternative to traditional EEG for seizure detection because they allow the patient to walk around.
Responsive Neurostimulation (RNS) is a groundbreaking surgical approach for treating medication-resistant seizures. A neurostimulator is implanted beneath the scalp and within the skull, and it is linked to two electrodes placed on the brain's surface, within the brain, or a mix of the two.
Electrocardiography measures the electrical activity of the heart. To accomplish this, electrodes are attached to the arms, legs, and chest. These electrodes detect electrical signals from the heart. An EKG just collects electrical impulses and does not emit any electrical signals, therefore it does not cause any harm to the patient.
In general, video detection systems work in tandem with EEG monitoring VEM (Video EEG Monitoring) to simultaneously capture a patient's behaviour and electrical activity in the brain (EEG). It is accomplished by the use of specialised equipment that records EEG, video, and sound onto a computer for analysis.
Electrodermal activity (EDA) is a useful sign for detecting epilepsy.
Seizure prediction could be clinically useful in epilepsy patients since it would increase safety and independence while also allowing for quick treatment. It is feasible to predict seizures with implanted advisory devices.
Other epilepsy diagnosis and prediction methods include External Trigeminal Nerve Stimulation (ETNS), High-Density EEG, Computerized Tomography (CT) scan, Magnetic resonance imaging (MRI), and Positron Emission Tomography (PET) scans.
Because of the availability of epilepsy gadgets and patients' propensity to visit hospitals and clinics, hospitals and clinics are predicted to rise significantly during the projection period. Furthermore, the progressive increase in the number of government and private hospitals around the world is fueling the expansion of this market.
Epilepsy diagnosis and monitoring necessitate complex and modern technologies, as well as skills to appropriately interpret the results and give appropriate therapy. Demand for neurology facilities for epilepsy diagnosis and treatment is driven by medical knowledge and advanced instruments such as EEG, MRI, and SPECT machines housed under one roof. Other end users of epilepsy devices include ambulatory surgery facilities, rehab centres, and nursing homes.
Boston Scientific Corporation, Koninklijke Philips N.V, Compumedics Ltd., Cerbomed GmbH, Neuropace Inc., Medtronic Plc., Nihon Kohden Corporation, St. Jude Medical, Inc., Natus Medical Incorporated, Medpage Ltd, Liva Nova, MC10, Empatica Inc.
by End User
by Product Type
Vagus Nerve Stimulation
Deep Brain Stimulation
by Epilepsy Detection & Prediction Devices
Video Detection Systems
Implanted Advisory Systems
Because of the huge number of enterprises operating in the region, North America is expected to have the largest share of the worldwide epilepsy devices market. Furthermore, government backing is projected to be critical in propelling the sector ahead. The worldwide epilepsy market will also experience significant increase as a result of rising healthcare expenditure and disease prevalence in the region.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2021||US$ 17.16 Billion|
|Market Size by 2028||US$ 31.47 Billion|
|CAGR||CAGR of 9.05% From 2022 to 2028|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• by End User (Hospitals, Neurology Centers, and Others)
• by Product Type (Wearable Devices, Conventional Devices, and Implantable Devices)
• by Technology (Vagus Nerve Stimulation (VNS), Responsive Neurostimulation, Deep Brain Stimulation, and Accelerometry), Epilepsy Detection & Prediction Devices (Electroencephalogram (EEG), Intracranial EEG, Surface Electromyography (sEMG), Electrodermal Activity (EDA), Electrocardiography (EKG), Video Detection Systems, Implanted Advisory Systems, and Others)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Boston Scientific Corporation, Koninklijke Philips N.V, Compumedics Ltd., Cerbomed GmbH, Neuropace Inc., Medtronic Plc., Nihon Kohden Corporation, St. Jude Medical, Inc., Natus Medical Incorporated, Medpage Ltd, Liva Nova, MC10, Empatica Inc.|
|Key Drivers||• Epilepsy is becoming more common in the elderly population.
• Increased occurrences of brain damage as a result of car accidents
|RESTRAINTS||• Epilepsy is a chronic neurological illness that can affect persons of any age.|
Frequently Asked Questions (FAQ) :
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID 19 Impact Analysis
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8.Epilepsy Device Market, by End User
8.2 Neurology Centers
9.Epilepsy Device Market, by Product Type
9.1 Wearable Devices
9.2 Conventional Devices
9.3 Implantable Devices
10.Epilepsy Device Market, by Technology
10.1 Vagus Nerve Stimulation
10.2 Responsive Neurostimulation
10.3 Deep Brain Stimulation
11.Epilepsy Device Market, by Epilepsy Detection & Prediction Devices
11.2 Intracranial EEG,
11.3 Surface Electromyography
11.4 Electrodermal Activity
11.6 Video Detection Systems
11.7 Implanted Advisory Systems
12. Regional Analysis
12.2 North America
12.3.6 The Netherlands
12.3.7 Rest of Europe
12.4.2 South Korea
12.4.6 Rest of Asia-Pacific
12.5 The Middle East & Africa
12.5.3 South Africa
12.6 Latin America
12.6.3 Rest of Latin America
13.1 Nihon Kohden Corporation
13.1.2 Products/ Services Offered
13.1.3 SWOT Analysis
13.1.4 The SNS view
13.2 St. Jude Medical, Inc.
13.3 Liva Nova
13.5 Boston Scientific Corporation,
13.6 Koninklijke Philips N.V
13.7 Medpage Ltd
13.8 Cerbomed GmbH
13.9 Compumedics Ltd.
13.10 Natus Medical Incorporated
14. Competitive Landscape
14.1 Competitive Benchmarking
14.2 Market Share analysis
14.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of the good and accurate research report and selecting the best methodology to complete the research is the toughest part. Since the research reports, we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brainstorming sessions to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploaded on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.